Spots Global Cancer Trial Database for Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
Official Title: Open-label, Multicenter Phase 1 Study of Mogamulizumab (KW-0761) in Combination With Docetaxel in Previously Treated Subjects With Non-small Cell Lung Cancer (NSCLC)
Study ID: NCT02358473
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety of mogamulizumab in combination with docetaxel in adult subjects with previously treated locally advanced or metastatic non-small cell lung cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Horizon Oncology, Lafayette, Indiana, United States
John Hopkins University School of Medicine, Baltimore, Maryland, United States
Gabrail Cancer Center Research, Canton, Ohio, United States
MD Anderson, Houston, Texas, United States
Cancer Therapy and Research Center, San Antonio, Texas, United States
Contact Details
Name: Michael Kurman
Affiliation: Kyowa Kirin, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
